Table 5.
St Type | St-Mc-DDS | Drug | Indication | Animal Model | Targeting Ability and Biodistribution | Tumor Volume | Tumor Mass | Body Weight | Ref. |
---|---|---|---|---|---|---|---|---|---|
pH | Polymer-drug conjugates | DOX | Breast cancer | Female BALB/c mice | Increased accumulation in tumors | 3.1-fold smaller | 54% TGI | Slow and steady increase | [81] |
Eph A10/TPP-DTX liposomes | Docetaxel | Breast cancer | Female BALB/c nude mice | Excellent targetability at tumor site | 1.23-fold smaller | Higher tumor inhibition efficacy | Slightly increase | [42] | |
CTPP-CSOSA/celastrol micelles | Celastrol | Breast cancer | Nude mice | Mainly concentrated in the liver and tumor, and increased in tumor as time prolonging | Smaller | 80.17% TGI | An increase to a certain extent | [43] | |
HER-2/DOX DQAsomes | DOX | Breast cancer | Nude mice bearing MCF-7/ADR model | Smaller | 72.5% TGI | No obvious weight loss | [36] | ||
PEG-AIE-TPP micelles | AIE-TPP | Breast cancer | Athymic nude female mice | Better aggregation in tumor site | Much Smaller | Better tumor inhibition efficacy | Gradually increase | [44] | |
HPMA-MSN/DTX nanoparticles | Docetaxel | Cervical cancer | HeLa cells tumor-bearing nude mice | Abundant tumor tissues accumulation | The growth of the tumors were suppressed | 72.6% TGI | No obvious change | [45] | |
TPP-Que-PEG nanoparticles | Quercetin | Liver cancer | H22 tumor-bearing Male ICR mice | High accumulation in tumor tissue | Smaller | 65.7% TGI | Increase rate is similar to control group | [46] | |
DSPE-KLA-DMA/PTX liposomes | Paclitaxel | Lung cancer | A549/Taxol cells xenografted onto nude mice | – | Smaller | 86.7% TGI | No weight loss | [47] | |
PDPA/TPGS/DOX micelles | DOX | Breast cancer | Nude mouse model bearing orthotopic tumor | Increased accumulation in tumors | 3.5-fold smaller | 3-fold less | No obvious weight loss | [48] | |
HHG2C18 liposomes | Temsirolimus (CCI-779) | Renal cancer | Murine Renca cell xenograft models | Increased accumulation in tumors | Smaller | – | – | [49] | |
CAT@S/Ce6-CTPP/DPEG | Catalase | Breast cancer | 4T1 tumor model | Increased accumulation in tumors | Smaller | – | No obvious variation | [20] | |
Redox | Glucose-PEG-peptide-TPP-PAMAM-PTX conjugates | Paclitaxel | Breast cancer | MCF-7/ADR tumor-bearing nude mice | Increased accumulation in tumors | Smaller | 84.27% TGI | Highest body weight increase | [78] |
TPP-OHA-S-S-Cur micelles | Curcumin | Breast cancer | – | – | – | – | – | [50] | |
PLGA/C18-PEG-TPP/DLPE-S-S-mPEG/PTX nanoparticles | Paclitaxel | Breast cancer | MCF-7 tumor bearing BALB/c nude mice | High accumulation in tumor tissue | Smaller | 90.5% TGI | No significant body weight loss | [51] | |
TPP-PPa micelles | PPa | Breast cancer | – | – | – | – | – | [76] | |
Enzyme | HA/PEG/berberine derivative nanodrugs | Berberine derivative | Lung cancer | A549 tumor-bearing BALB/c nude mice | High accumulation at the tumor location | Smaller | 61.7% TGI | No significant differences in body weight | [19] |
Non-isocyanate polyurethane-TPP/DOX nanocapsule | DOX | Brain cancer | Zebrafish embryo | – | – | – | – | [52] | |
TPP-peptide nanoassemblies | TPP-peptide | Osteosarcoma cancer | – | – | – | – | – | [53] | |
Light | Perfluorooctyl bromide/IR780 liposomes | IR780 | Breast cancer | 4T1 tumor-bearing nude mice | The effective accumulation in tumor tissues | Smaller (complete tumor elimination) | Better tumor inhibition efficacy | Negligible weight fluctuations | [54] |
Iridium/Fe3O4 nanozyme | Iridium | Cervical cancer | HeLa tumor-bearing mice | – | Smaller | Better tumor inhibition efficacy | No significant body weight loss | [55] | |
IR-780/DSPE-PEG2K-TPP liposomes | IR-780; Lonidamine | Lung cancer | LL/2 tumor-bearing mice | High accumulation in tumor tissue | Smaller (complete eradication) | Better tumor inhibition efficacy | A slight reduction | [56] | |
AuNS-KLA-TPP/HA/DOX nanoparticles | DOX | Squamous carcinoma | SCC-7 tumor-bearing BALB/c nude mice | Effective tumor accumulation | Smaller | Better tumor inhibition efficacy | No obvious body weight reduction | [58] | |
TPP/Ce6/PEG-/FA-PEG-Pt@Au nanoparticles | Ce6 | Breast cancer | – | – | – | – | – | [59] | |
PPa-NGO-mAb nanodrug | PPa | Brain cancer | – | – | – | – | – | [64] | |
Yb/Tm/TiO2 nanoparticles | Yb/Tm/TiO2 | Cervical cancer | Xenograft HeLa tumor models | – | Smaller (a much slower growth rate) | Good tumor growth inhibition efficacy | – | [65] | |
TPP-coumarin-Fe3O4 nanoparticles | Fe3O4 | Cervical cancer | A549 cell xenografted BALB/c nude mice | Accumulated at the tumor site | A more dramatic decrease | – | – | [66] | |
Magnetic field | DNA/PK-CP-SPION complexes | DNA | Cervical cancer | – | – | – | – | – | [69] |
Abbreviations: DOX, doxorubicin; TGI, tumor growth inhibition.